Researchers assessed the Pan-Immune-Inflammation Value (PIV) as an indicator of neoadjuvant immunochemotherapy (NICT) response in esophageal squamous cell carcinoma. Among 218 patients, PIV was linked to achieving a pathological complete response. High PIV predicted poorer 3-year overall survival and disease-free survival compared to low PIV. PIV independently forecasted outcomes. A novel risk stratification model improved prognosis accuracy. This suggests that pretreatment PIV is a sensitive predictor for NICT effectiveness in esophageal cancer. Further prospective studies are needed to confirm these prognostic results.
Journal Article by Feng J, Wang L (…) Cheng X et 2 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.